Investigators accessed longitudinal human data from ebola virus vaccination for signals of efficacy against the Bundibugyo species now surging in the Democratic Republic of Congo.
|Articles|February 3, 2020
Study Supports Minimal Monitoring in Sofosbuvir-Based Therapy for HCV
Author(s)Jonna Lorenz
Minimal monitoring of patients receiving sofosbuvir-based therapy for hepatitis C virus resulted in equal cure rates at less cost than standard monitoring, a new study found.
Advertisement
Some patients receiving sofosbuvir-based therapy for hepatitis C virus (HCV) may not need standard monitoring with clinic visits and blood testing, according to a new study that showed minimal monitoring resulted in equal cure rates at less cost.
The study,
The randomized controlled trial included 74 patients receiving oral direct acting antiviral agents (DAA) at 2 Australian teaching hospitals enrolled in the study between December 2016 and December 2017.
“Uncomplicated patients being treated with oral DAA regimens for HCV only require minimal monitoring, with routine clinic visits and blood tests only needed at baseline and 3 months after the end of treatment,” Josh Davis, MBBS, FRACP, DTM&H, GCPopHealth, PhD, of the Menzies School of Health Research told Contagion®.
The study included 36 patients who received standard monitoring and 38 who received minimal monitoring.
Sustained virologic response (SVR) tests after 12 weeks of treatment (SVR12) showed no significant differences between the group that received minimal monitoring (97% [95% CI, 86%—100%]) and those who received standard monitoring (89% [95% CI, 74%–97%]) when those with missing SVR data were assumed to be failures. All patients in both groups achieved SVR12 when those with missing SVR data were disregarded.
Staff time and patient satisfaction also were similar in both groups. Total staff time was reduced by 17 minutes—69 minutes in the standard monitoring group compared with 52 minutes in the minimal monitoring group. Overall patient satisfaction scores on a 10-point Likert scale were 9.8 in the standard monitoring group and 9.6 in the minimal monitoring group.
There were no significant differences in adverse events between the two groups. The total cost of blood tests averaged $432 in the standard monitoring group compared with $123 in the minimal monitoring group.
Standard monitoring may be necessary for some patients whose cases are more complicated.
“These results don’t apply to complex patients including those with current substance use disorders, active mental illness or decompensated cirrhosis—these patients likely need closer monitoring,” Davis told Contagion®.
He said decisions should be made on a case-by-case basis.
“Clinics and primary care practitioners who treat HCV patients should stop doing routine on-treatment blood tests and/or clinic visits, and make individualized monitoring plans for each patient,” Davis told Contagion®.
The research ended up supporting shifts in clinical practice that began before the study’s completion, so further research to confirm the results is unlikely.
“There was a drift in clinical practice during the course of the trial, so that many clinicians, and even guidelines, changed to recommending minimal monitoring, in advance of the evidence!” Davis told Contagion®.
The incidence of HCV has risen during the past decade and causes about 20,000 deaths annually in the United States. To increase the number of people infected with HCV who receive antiviral therapy,
The high cost of drugs has been 1 factor limiting access to treatment. A
Advertisement
Related to this article
In the first episode of our news series looking at the food safety network, Lynette Johnston, PhD, offers insights into how the federal government surveillance infrastructure operates, and how epidemiologists serve as food detectives in determining bacterial pathogens and potential foodborne outbreaks.
In mid-May, as the world was still grappling with an unexpected hantavirus outbreak aboard a tourism vessel, news broke of an Ebola outbreak in the Ituri Province of the Democratic Republic of the Congo spanning at least 3 health zones, including Bunia, Rwampara, and Mongbwalu.
In this week's top infectious disease stories, a Pennsylvania teen became the state's fourth measles death in weeks, the CDC reported a 17% summer surge in rabies exposure calls, new research revisited whether cefepime raises mortality risk, a multihospital review examined ceftriaxone's safety after state alerts, and examining Legionella pneumonia diagnostics.
The latest CDC numbers show a 5.37% increase of measles cases from week-to-week. In Pennsylvania, the fourth measles-related death was reported in 2026. Additionally, the CDC has made a change in the way it will report deaths.
A "Clinician Outreach" from the Centers for Disease Control and Prevention (CDC) in April anticipated an increase in rabies exposures, and the striking surge in case reports this summer prompted a recent health advisory alert from the federal agency.
Reported cases of Legionnaires’ disease have been on the rise for the past decade, and identifying Legionella bacteria requires specialized testing in the microbiology lab. Here is a clinical overview of Legionella bacteria, including required testing, treatment, and reporting to public health officials.
A retrospective multihospital study found that severe adverse events occurred at similarly low rates with ceftriaxone and other IV cephalosporins suggesting there is no evidence to support avoiding ceftriaxone despite recent health department safety alerts.